-
公开(公告)号：US12048718B2
公开(公告)日：2024-07-30
申请号：US16307854
申请日：2017-06-07
发明人： Armin Rehm , Uta Elisabeth Höpken , Julia Bluhm , Wolfgang Uckert , Elisa Kieback , Stephen Marino
CPC分类号： A61K35/17 , A61K47/65 , C07K14/70596 , C07K16/2878 , C12N15/62 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/622 , C07K2317/73 , C07K2319/03
摘要： The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.
-
公开(公告)号：US20210079108A1
公开(公告)日：2021-03-18
申请号：US17079075
申请日：2020-10-23
发明人： Felix Oden , Stephen Marino , Oliver Daumke
摘要： A nucleic acid molecule encoding an antibody or antibody fragment, wherein the antibody or antibody fragment binds an epitope of the extracellular domain of CD269 (BCMA), a host cell comprising the nucleic acid molecule and a composition comprising the host cell.
-
公开(公告)号：US20170166649A1
公开(公告)日：2017-06-15
申请号：US15306438
申请日：2015-04-30
发明人： Felix Oden , Stephen Marino , Oliver Daumke
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K47/6849 , A61K47/6867 , A61K2039/505 , A61K2039/545 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The invention relates to humanized antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
-
公开(公告)号：US11820829B2
公开(公告)日：2023-11-21
申请号：US17079075
申请日：2020-10-23
发明人： Felix Oden , Stephen Marino , Oliver Daumke
CPC分类号： C07K16/2878 , A61K47/6849 , A61K47/6867 , A61K39/395 , A61K2039/505 , A61K2039/545 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C12N5/10 , C12N15/00
摘要： A nucleic acid molecule encoding an antibody or antibody fragment, wherein the antibody or antibody fragment binds an epitope of the extracellular domain of CD269 (BCMA), a host cell comprising the nucleic acid molecule and a composition comprising the host cell.
-
公开(公告)号：US20190112382A1
公开(公告)日：2019-04-18
申请号：US16170575
申请日：2018-10-25
发明人： Felix Oden , Stephen Marino , Oliver Daumke
摘要： A method of treating a medical disorder associated with the presence of pathogenic B cells expressing B cell maturation antigen (BCMA), the method comprising administering to a subject an isolated antibody or antibody fragment comprising specific VH and VL domain complementary determining region (CDR) sequences, wherein the antibody or fragment thereof specifically binds an epitope of the extracellular domain of CD269 (BCMA)
-
公开(公告)号：US11667722B2
公开(公告)日：2023-06-06
申请号：US16923726
申请日：2020-07-08
发明人： Martin Lipp , Felix Oden , Uta Höpken , Gerd Müller , Oliver Daumke , Stephen Marino , Daniel Olal
CPC分类号： C07K16/2878 , A61K47/6867 , A61P35/00 , C07K16/3061 , A61K39/395 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： A composition comprising a cell or a population thereof, wherein the cell comprises a polynucleotide encoding an antibody or a fragment thereof that binds CD269 (BCMA), wherein the binding to CD269 (BCMA) disrupts the interaction between CD269 and its native ligands (BAFF and APRIL). Also disclosed is treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
-
公开(公告)号：US10851172B2
公开(公告)日：2020-12-01
申请号：US16170575
申请日：2018-10-25
发明人： Felix Oden , Stephen Marino , Oliver Daumke
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395 , A61K47/68 , A61K39/00
摘要： A method of treating a medical disorder associated with the presence of pathogenic B cells expressing B cell maturation antigen (BCMA), the method comprising administering to a subject an isolated antibody or antibody fragment comprising specific VH and VL domain complementary determining region (CDR) sequences, wherein the antibody or fragment thereof specifically binds an epitope of the extracellular domain of CD269 (BCMA).
-
公开(公告)号：US10144782B2
公开(公告)日：2018-12-04
申请号：US15306438
申请日：2015-04-30
发明人： Felix Oden , Stephen Marino , Oliver Daumke
IPC分类号： C07K16/18 , A61K39/395 , C07K16/28 , A61K47/68 , A61K39/00
摘要： The invention relates to humanized antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.019 秒)
